Disease Education
Discover Pro-tumor Inflammation (PTI) and Understand MET in Lung Cancer
Learn More about PTI as a Driver of Tumor Growth, Survival, and Progression
Understanding MET in NSCLC
Discover IL-1β Inhibition, Immunotherapy, and Targeted Therapy in Lung Cancer
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.
Explore Clinical Trials
Explore Clinical Trials
Neoadjuvant NSCLC
CANOPY-N
Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neoadjuvant Treatment for Subjects With Early Stages NSCLC
Adjuvant NSCLC
CANOPY-A
Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v.8 II-IIIA and IIID(T>5cm N2) Completely Resected Non-small Cell Lung Cancer
2L+ NSCLC
GEOMETRY-E
Capmatinib + Osimertinib vs Platinum Chemo in EGFP Resistant MET+ Advanced NSCLC
Neoadjuvant and Adjuvant
GEOMETRY-N
Study of Neoadjuvant and Adjuvant Capmatinib in Adult Subjects With Stages IB-IIIA, N2, and Selected IIIB (T3N2 or T4N2) NSCLC With METex14 Mutation or High MET Amplification
2L+
NCT04699188
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Explore Compounds
Explore Compounds
Canakinumab (ACZ885)
Selective IL-1β inhibitor
Capmatinib (INC280)
MET receptor tyrosine kinase inhibitor
JDQ443
KRAS G12C small molecule inhibitor
Spartalizumab (PDR001)
PD-1–targeting monoclonal antibody
Tislelizumab
PD-1–targeting monoclonal antibody
TNO155
Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2) inhibitor
